Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 32 of 6351
-
Can a Two-Drug immunotherapy combo shrink MSS colon cancer before surgery?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has n…
Phase 2 • Sponsor: Solstice Oncology, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
One-Time gene injection aims to halt rare blindness
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the safety and early effectiveness of ZVS101e in patients with Bietti crystalline dystrophy who meet the eligibility criteria for treatment under the translational application program in the Hainan Boao Lecheng International Medical …
Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Tiny heart implant aims to unclog lungs and save lives in advanced heart failure
Disease control Not yet recruitingThis study will evaluate the V-Wave Ventura Interatrial shunt. The Shunt is a small, hourglass-shaped device implanted in the dividing wall (septum) between the right and left atria (top chambers) of the heart placed during a minimally invasive cardiac catheterization procedure. …
Sponsor: V-Wave Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New eye drug aims to restore vision in Diabetes-Related swelling
Disease control Not yet recruitingResearchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Brain cancer vaccine targets survivin protein to boost immune attack
Disease control Not yet recruitingThe overall objective of this study is to preliminarily evaluate the efficacy and safety of Survivin-targeted DC Cell Injection in the postoperative treatment of newly diagnosed glioblastoma.
Phase 2 • Sponsor: Beijing Tricision Biotherapeutics Inc • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immunotherapy may treat skin cancer in kidney transplant patients without rejection
Disease control Not yet recruitingThis is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma. The hypothesis being tested is that cemipli…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a vaccine train the immune system to hunt down hidden breast cancer cells?
Disease control Not yet recruitingThis phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden. TNBC has an aggressive clinical course and poorer dise…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a targeted drug combo outsmart advanced head and neck cancer?
Disease control Not yet recruitingHead and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combinat…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can tighter blood pressure control in pregnancy prevent serious complications?
Disease control Not yet recruitingThis is a phase-III multi-center open-label randomized clinical trial of 4,120 individuals between 23 weeks, 0 days and 35 weeks, 6 days gestation with gestational hypertension or preeclampsia without severe features randomized to antihypertensive medication to a target blood pre…
Phase 3 • Sponsor: The George Washington University Biostatistics Center • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Can a new drug combo outperform standard care for a tough blood cancer?
Disease control Not yet recruitingThis randomized, open label, multi arm phase II trial will evaluate the efficacy and safety of venetoclax based induction regimens of varying intensity (VA, VAM, or 2+5+V) versus standard 3+7 in fit patients aged ≥14 years with newly diagnosed AML. The trial is designed to select…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new drug combo shrink liver tumors?
Disease control Not yet recruitingThis is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
Disease control Not yet recruitingThis study is a single-arm, exploratory clinical trial, aiming to include patients with HER2-positive advanced breast cancer. It intends to explore the efficacy and safety of trastuzumab combined with pyrotinib, capecitabine ± endocrine therapy as a first-line maintenance treatme…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a weekly shot reverse type 2 diabetes?
Disease control Not yet recruitingThe purpose of this study is to investigate and efficacy of Mastitide for diabetes remission in Chinese type 2 diabetic subjects with poor glycemic control on diet or exercise therapy alone or metformin/sodium-glucose cotransporter (SGLT2) inhibitor monotherapy.
Sponsor: Yanbing Li • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a targeted drug combo outsmart returning ovarian cancer?
Disease control Not yet recruitingThis study is a randomized, open-label, controlled phase II clinical trial. It is planned to enroll 176 subjects with platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer previously treated with Poly (ADP-ribose) polymerase …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a Two-Pronged attack shrink advanced solid tumors?
Disease control Not yet recruitingResearchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced may mean the cancer has spread to nearby or other parts of the body. The cancer may …
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new pill slow advanced breast cancer in patients with a key gene mutation?
Disease control Not yet recruitingThis is a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JYP0035 Capsules in Combination With Fulvestrant in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Pr…
Phase 3 • Sponsor: Chengdu JOYO pharma Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a targeted drug duo boost the power of surgery for stomach cancer?
Disease control Not yet recruitingThis two-stage, multicenter, randomized open-label phase II trial enrolls untreated resectable stage II-III gastric/gastroesophageal junction adenocarcinoma patients with any HER2 expression. Stage 1 is a safety lead-in cohort of 6 patients receiving Trastuzumab Rezetecan(SHR-A18…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo aims to stop repeat strokes in High-Risk patients
Prevention Not yet recruitingCATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for 90 days followed by placebo plus aspirin daily for …
Phase 3 • Sponsor: Population Health Research Institute • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
Can a new Immune-Boosting drug shrink advanced solid tumors?
Disease control Not yet recruitingResearchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be remov…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a monthly shot help people with obesity lose weight?
Disease control Not yet recruitingThe purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition in which a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some participant…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC